Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2009 Apr;11(2):116-23.

Progress toward therapy with antisense-mediated splicing modulation.

Author information

1
Department of Pathology and Laboratory Medicine, The David Geffen School of Medicine at UCLA, 675 Charles Young Drive South, CA 90095-1732, USA. ldu@mednet.ucla.edu

Abstract

Antisense oligonucleotides (AO) or antisense RNA can complementarily bind to a target site in pre-mRNA and regulate gene splicing, either to restore gene function by reprogramming gene splicing or to inhibit gene expression by disrupting splicing. These two applications represent novel therapeutic strategies for several types of diseases such as genetic disorders, cancers and infectious diseases. In this review, the recent developments and applications of antisense-mediated splicing modulation in molecular therapy are discussed, with emphasis on advances in antisense-mediated splice targeting, applications in diseases and systematic delivery.

PMID:
19330717
PMCID:
PMC2753608
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center